Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05690503 · ClinicalTrials.gov registry record · Phase 2
Glutamatergic Modulation as a Treatment for Depressive Symptoms Among Patients With Post-acute Sequelae of COVID (PASC): A Pilot Trial
A Phase 2 study of Depressive Symptoms and Cognitive Dysfunction, sponsored by New York State Psychiatric Institute.
- Active
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT05690503: Active Phase 2 study of Depressive Symptoms and Cognitive Dysfunction, sponsored by New York State Psychiatric Institute.
NCT05690503 is a Phase 2 study of Depressive Symptoms and Cognitive Dysfunction that is active but no longer recruiting, run by New York State Psychiatric Institute. The registered enrollment target is 12 participants, below the 262-participant average among 60 other Depressive Symptoms trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05690503, a Phase 2 study of Depressive Symptoms and Cognitive Dysfunction, is active but no longer recruiting, sponsored by New York State Psychiatric Institute.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
Post-acute sequelae of SARS-CoV2 (PASC), colloquially known as "long-COVID," is thought to affect between 10-30% of all COVID-19 survivors. Patients with PASC also report worsening behavioral health symptoms over time that include new-onset depression, anxiety, and even suicidal behavior. The purpose of this randomized, double-blind, controlled trial is to test the efficacy of a glutamate modulator among PASC patients suffering from new-onset or worsening of depressive symptoms.
Conditions Studied
Interventions
- DRUG CI-581a
- DRUG CI-581b
Study Locations (1)
New York
- New York State Psychiatric Institute - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2023-03-20 |
| Est. Completion | 2025-12-31 |
| Phase | Phase 2 |
What the registry record for NCT05690503 still lists
NCT05690503 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 262-participant average among 60 other Depressive Symptoms trials with a reported enrollment target (95% lower).
The record links to 3 conditions, with Depressive Symptoms appearing as the primary indexed condition, and to 2 interventions - of which CI-581a is the first listed.
NCT05690503 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT05690503 about?
NCT05690503 is a clinical study titled "Glutamatergic Modulation as a Treatment for Depressive Symptoms Among Patients With Post-acute Sequelae of COVID (PASC): A Pilot Trial". Post-acute sequelae of SARS-CoV2 (PASC), colloquially known as "long-COVID," is thought to affect between 10-30% of all COVID-19 survivors. Patients with PASC also report worsening behavioral health symptoms over time that include new-onset depression, anxiety, and even suicidal behavior. The purpos...
What is the current status of trial NCT05690503?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2023-03-20. Estimated completion is 2025-12-31.
What conditions does trial NCT05690503 study?
This clinical trial studies the following conditions: Depressive Symptoms, Cognitive Dysfunction, Post Acute Sequelae of COVID-19.
What interventions are being tested in trial NCT05690503?
The interventions under investigation include: CI-581a (DRUG), CI-581b (DRUG).
Who is sponsoring clinical trial NCT05690503?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05690503 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depressive Symptoms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05690503's enrollment target sits among peer trials
12 58th of 60 higher than 3 of 60 other Depressive Symptoms trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Depressive Symptoms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Cannabidiol for Reduction of Brain Neuroinflammation
RECRUITING · Phase 2
-
Beating the Blues for Your Heart
COMPLETED · Phase 2
-
Study to Evaluate TNX-601 ER Monotherapy Versus Placebo in Patients With Major Depressive Disorder (MDD)
COMPLETED · Phase 2
-
Acute and Long-Term Antidepressant Treatment Success in Adolescents With Anxiety (AtLAS-A)
RECRUITING · Phase 4
-
Caregiver Stress and Sleep Study
RECRUITING · NA
-
IMPACT (IMproving Proactive Approaches for Cancer Survivors' Mental Health Treatment)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI